Structure Therapeutics logo

Structure Therapeutics

GPCR | NASDAQ
Chart Builder DCF Calculator
$18.57
-$1.43 (-7.15%)
At close: Nov 16, 2026, 4:00 PM ET
$18.56
-$0.01 (-0.05%)
After-hours: Nov 16, 2026, 7:30 PM ET
-7.15%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
26.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #890/1021 (Top 87%)

Key Statistics

Market Data

Market Cap $1.35B
1D Range
18.38 19.99
52W Range
18.38 93.79

Valuation (TTM)

PE -4.76
PB 1.11
EV/EBITDA -0.41

Valuation (NTM)

Forward PE N/A
Forward PEG -0.05
Price Target $90.50
Loading financial charts...

Profile

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various ch...

Sector Healthcare
Industry Biotechnology
Employees 281
IPO Date Feb 3, 2023
Fiscal Year January - December

Latest News

Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

7 days ago · globenewswire.com

Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?

8 days ago · zacks.com

Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026

28 days ago · globenewswire.com

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

1 month ago · zacks.com

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Structure Therapeutics: The Amylin Data Changes The Math

2 months ago · seekingalpha.com

Structure Therapeutics: The Amylin Data Changes The Math
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

2 months ago · seekingalpha.com

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

3 months ago · seekingalpha.com

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

5 months ago · seekingalpha.com

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure's experimental obesity pill shows no signs of liver injury

5 months ago · reuters.com

Structure's experimental obesity pill shows no signs of liver injury

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$90.50
Upside
+387.35%
Buy (9)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.